TITLE

Vioxx: lessons for Health Canada and the FDA

PUB. DATE
January 2005
SOURCE
CMAJ: Canadian Medical Association Journal;1/4/2005, Vol. 172 Issue 1, p3
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
Comments on the withdrawal of the COX-2 inhibitor rofecoxib from the market in September 2004 because of an increased risk of cardiovascular disease. Impact of revelations about the drug's risk on the market value of Merck & Co. Inc.; Critique of the drug approval policy; Shortcomings of the Food and Drug Administration and Health Canada on their public mandates.
ACCESSION #
15414634

 

Related Articles

  • Vioxx.  // Formulary;May2004, Vol. 39 Issue 5, p235 

    Provides information on Merck & Co. Inc.'s cyclooxygenase-2 inhibitor Vioxx, or rofecoxib, which has been approved by the U.S. Food and Drug Administration for the treatment of migraine. Mechanism of action; Drug efficacy; Safety; Dosing.

  • FDA requests further data on Merck's Arcoxia application.  // PharmaWatch: CNS;December2004, Vol. 3 Issue 12, p16 

    Reports that the U.S. Food and Drug Administration has informed Merck & Co. that it will require further safety and efficacy information before granting approval of Merck's new drug application for the COX-2 inhibitor, Arcoxia. Company's revision of its new drug application to the agency to...

  • Blow for Merck as FDA rejects Arcoxia.  // TCE: The Chemical Engineer;May2007, Issue 791, p5 

    The article reports that an advisory committee to the U.S. Food and Drug Administration (FDA) has recommended that Merck's cyclooxygenase-2 inhibitor, Etoricoxib, should not be approved. The committee pointed out that the risks associated with the drug, commonly known as Arcoxia, outweigh its...

  • Out of sight. McLaughlin, Neil // Modern Healthcare;10/18/2004, Vol. 34 Issue 42, p26 

    Focuses on the problems facing the pharmaceutical industry in the U.S. Recall of Vioxx cyclooxygenase 2 inhibitor by Merck & Co.; Flu vaccine debacle; Emergence of reports on price gouging.

  • Vioxx withdrawal spurs rivals into action. McGuire, Stephen // Medical Marketing & Media;Nov2004, Vol. 39 Issue 11, p12 

    This article reports that in the wake of Merck & Co. Inc.'s decision to withdraw Vioxx because of unfavorable clinical trials data, Pfizer and Boehringer Ingelheim/ Abbot Laboratories' stepped up efforts to promote their respective rival COX- 2 inhibitors, Celebrex and Mobic. Merck had pulled...

  • Will the FDA's axe fall on COX-2s?  // PharmaWatch: Monthly Review;Feb2005, Vol. 4 Issue 2, p23 

    The article reports on the effects of the controversies about the cardiovascular dangers of cyclooxygenase-2 inhibitors on the pharmaceutical industry. The withdrawal of Merck & Co.'s Vioxx from the market because of these concerns has brought shockwaves in the sector. Pfizer Inc. has also...

  • Courts spell further trouble for COX-2. Houlton, Sarah // European Pharmaceutical Executive;Nov/Dec2005, p6 

    The article discusses court cases faced by pharmaceutical companies manufacturing COX-2 inhibitors. A woman in Texas was compensated by Merck & Co. Inc. due to the death of her husband allegedly from Vioxx side-effects. A second legal battle is under way in New Jersey. Merck claims that it can...

  • Merck s Loss Could Turn Out to be Pfizer's Gain.  // Chemical Market Reporter;10/11/2004, Vol. 266 Issue 12, p12 

    Reports that Merck & Co.'s recall of the drug Vioxx (rofecoxib), a Cox-2 inhibitor, could actually boost the revenue at Pfizer Inc.. Confidence that patients will not abandon Cox-2 inhibitor drugs completely; Pfizer's competing Cox-2 inhibitors, Celebrex and Bextra; Patient safety concerns

  • The Impact of Vioxx on US drug regulation.  // Reactions Weekly;12/3/2005, Issue 1080, p2 

    The article discusses research being done on the impact Merck & Co's Vioxx on U.S. drug regulations. It references a study by T. Zwillich published in the November 19, 2005 issue of "Lancet." Merck & Co.'s COX-2 inhibitor Vioxx has been accused of resulting to a myocardial infarction or...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics